ArticleNeoplasia (New York, N.Y.)2005
Activating mutations and/or expression levels of tyrosine kinase receptors GRB7, RAS, and BRAF in testicular germ cell tumors.
Article in Neoplasia (New York, N.Y.), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 81 citations in OpenAlex.
- Spontaneous Necrosis of a High-Risk Bladder Tumor Under Immunotherapy for Concurrent Malignant Melanoma: Role of BRAF Mutations and PD-L1 Expression.Biomedicines · 2025Article
- Comparison of clinical characteristics of testicular tumor between children and adult population: a retrospective analysis.BMC cancer · 2024Article
- RAS/Mitogen-Activated Protein Kinase Signaling Pathway in Testicular Germ Cell Tumors.Life (Basel, Switzerland) · 2024Review
- Somatic mutation detection andFrontiers in oncology · 2023Article
- Genomic features of mediastinal germ cell tumors: a narrative review.Mediastinum (Hong Kong, China) · 2022Review
- Up-regulated GRB7 protein in gastric cancer cells correlates with clinical properties and increases proliferation and stem cell properties.Frontiers in oncology · 2022Article
- Review
- Review
- Genomic landscape of platinum resistant and sensitive testicular cancers.Nature communications · 2020Article
- EGF Receptor and mTORC1 Are Novel Therapeutic Targets in Nonseminomatous Germ Cell Tumors.Molecular cancer therapeutics · 2018Article
- IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.The Journal of pathology · 2018Article
- Review
- Testicular cancer: biology and biomarkers.Virchows Archiv : an international journal of pathology · 2014Review
- Dissecting GRB7-mediated signals for proliferation and migration in HER2 overexpressing breast tumor cells: GTP-ase rules.American journal of cancer research · 2013Article
- MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.Molecular cancer therapeutics · 2012Article
- Testicular germ cell tumours: predisposition genes and the male germ cell niche.Nature reviews. Cancer · 2011Review
- Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer.The Journal of clinical investigation · 2010Article
- Chemotherapy for patients with poor prognosis germ cell tumors.World journal of urology · 2009Review
- [Advances in basic research on testicular germ cell tumors : clinical implications].Der Urologe. Ausg. A · 2009Review
- RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A.Neoplasia (New York, N.Y.) · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amplification and/or overexpression of genes encoding tyrosine kinase receptors KIT and ERBB2 have been reported in testicular germ cell tumors (TGCTs). These receptors can bind the adaptor molecule GRB7 encoded by a gene adjacent to ERBB2 at 17q12, a region also frequently gained in TGCTs. GRB7 binding may be involved in the activation of RAS signaling and KRAS2 maps to 12p, which is constitutively gained in TGCT and lies within a minimum overlapping region of amplification at 12p11.2-12.1, a region we have previously defined. RAS proteins activate BRAF, and activating mutations of genes encoding these proteins have been described in various tumors. Here we determine the relationships between expression levels and activating mutations of these genes in a series of 65 primary TGCTs and 4 TCGT cell lines. High levels of expression and activating mutations in RAS were mutually exclusive events, and activating mutations in RAS were only identified in the seminoma subtype. Mutations in BRAF were not identified. Increased ERBB2 expression was associated with differentiated nonseminoma histology excised from lymph nodes postchemotherapy. Mutation, elevated expression, and correlations between expression levels of KRAS2, GRB7, and KIT are consistent with their involvement in the development of TGCTs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.